# Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

> **NCT03210662** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Recurrent Aggressive Non-Hodgkin Lymphoma
- Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent T-Cell Non-Hodgkin Lymphoma
- Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Refractory Aggressive Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Refractory T-Cell Non-Hodgkin Lymphoma
- Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

## Interventions

- **RADIATION:** External Beam Radiation Therapy
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03210662
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-01
- **Primary completion:** 2025-10-28
- **Final completion:** 2025-10-31
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03210662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03210662, "Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03210662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*